Endocannabinoid system and gut flora

The endocannabinoid system briefly explained

The Endocannabinoid System (ECS) is an endogenous regulatory system that plays a central role in maintaining physiological balance (homeostasis). It is involved in a variety of fundamental processes, including pain processing, immune response, inflammation regulation, metabolism, stress reactions, and the control of functions in the digestive tract.

What are the central components of the endocannabinoid system?

Classically, the ECS consists of three main components:

What are endocannabinoids and what functions do anandamide and 2-AG have?

These are endogenous, biologically active lipid molecules. The two most important are

Anandamide (AEA) and 2-arachidonoylglycerol (2-AG). They are synthesized on demand from membrane lipids and act locally and temporarily.

What role do CB1 and CB2 receptors play in the endocannabinoid system?

The effects of endocannabinoids are primarily mediated via two G-protein-coupled receptors:

• CB1 receptors, which are mainly found in the central and enteric nervous systems and modulate neuronal signal transmission.
• CB2 receptors, which are predominantly expressed on immune cells and inflammation-related structures and perform immunomodulatory functions.

Both receptor types are also widespread in the gastrointestinal tract.

What roles do synthesis and degradation enzymes like FAAH and MAGL play?

Enzymes such as FAAH (Fatty Acid Amide Hydrolase) and MAGL (Monoacylglycerol Lipase) control the breakdown of anandamide and 2-AG respectively, thus limiting the signaling effect of endocannabinoids.

What is meant by the endocannabinoidome (eCBome)?

Modern research shows that the ECS is part of a significantly more complex network called the endocannabinoidome (eCBome). This includes, besides anandamide and 2-AG, numerous endocannabinoid-like lipid mediators as well as other target structures, including:

• TRP channels (e.g., TRPV1),
• nuclear receptors such as PPARs,
• other G-protein-coupled receptors (e.g., GPR55).

This extension explains why cannabinoids – especially non-psychoactive substances like CBD – can exert diverse biological effects without acting exclusively through classical CB1 or CB2 receptors.

How does the endocannabinoid system function in the context of homeostasis?

The endocannabinoid system operates mainly on demand: endocannabinoids are not stored but produced locally in response to physiological disturbance or stress. The goal is to limit excessive activity – for example, in inflammation, pain, or neuronal overexcitation – through inhibitory or balancing signals and to restore equilibrium. This regulatory function makes the ECS a central link between the nervous system, immune system, metabolism, and – as further described – the digestive tract and gut microbiome.

Significance of the Endocannabinoid System in the Digestive Tract

The digestive tract is one of the organs with the highest density of components of the endocannabinoid system (ECS). Both cannabinoid receptors and endogenous ligands and their metabolic enzymes can be detected along the entire gastrointestinal tract. This broad expression underscores the central importance of the ECS for regulating gastrointestinal functions and maintaining intestinal homeostasis.

Where are CB1 and CB2 receptors localized in the intestine and functionally involved?

CB1 and CB2 receptors are found in the enteric nervous system, in epithelial intestinal cells, on immune cells of the mucosa, and in smooth muscle. This means the ECS is involved in several levels of intestinal function: neuronal control, immunological regulation, and barrier function. This integrative position allows the system to respond in a coordinated manner to very different stimuli – such as food intake, microbial signals, or inflammatory processes.

How does the endocannabinoid system regulate intestinal motility and secretion?

One of the central tasks of the ECS in the digestive tract is the modulation of intestinal motility. Endocannabinoids predominantly act to inhibit the neuronal excitability of the enteric nervous system. This contributes to the fine-tuning of peristalsis and transit time and prevents excessive motor activity. At the same time, the ECS influences the secretion of electrolytes and fluids into the intestinal lumen, which is important for balanced digestion and stool consistency.

What role does the ECS play in protecting the intestinal barrier?

The endocannabinoid system also plays an important role in the integrity of the intestinal mucosal barrier. Through effects on epithelial cells and tight junction proteins, it contributes to stabilizing the intestinal wall and can limit permeability to bacterial components. This protective function is particularly relevant in the context of inflammatory processes, as a disrupted barrier is considered a central mechanism in chronic intestinal diseases.

How does the endocannabinoid system influence immune responses and inflammation in the gut?

Immune cells of the intestinal mucosa primarily express CB2 receptors. Their activation is associated with a suppression of proinflammatory signaling pathways and modulation of cytokine release. The ECS thus acts not primarily as immunosuppressive but as regulatory: it limits excessive inflammatory reactions without completely suppressing local defense functions.

What is the significance of the ECS in functional and inflammatory bowel diseases?

Due to these diverse functions, the ECS is considered a central regulatory system in functional disorders of the digestive tract as well as in inflammatory bowel diseases. Changes in endocannabinoid signaling are interpreted in this context as an adaptive response to stress, inflammation, or altered microbial stimuli.

Overall, the endocannabinoid system in the digestive tract functions as a finely tuned control system that links motility, barrier function, immune response, and neuronal signaling. This integrative role forms the basis for understanding the later interactions between the ECS, gut microbiome, and cannabinoids such as CBD.

How are the gut microbiome and the endocannabinoid system connected?

The relationship between the gut microbiome and the endocannabinoid system (ECS) is now understood as a bidirectional regulatory axis. Both systems influence each other and jointly contribute to the control of inflammation, barrier function, metabolism, and neuronal signaling in the gut. In recent literature, this functional connection is increasingly described within the framework of the extended endocannabinoidome (eCBome).

How does the gut microbiome influence endocannabinoid signaling?

Experimental and clinically oriented studies show that the composition and metabolic activity of the gut microbiome can significantly influence endocannabinoid signaling. Changes in microbial diversity or specific bacterial metabolites are associated with altered concentrations of endocannabinoids and endocannabinoid-like lipids. These lipid mediators in turn regulate processes such as gut permeability, immune activity, and neuronal signal transmission.

What role do dysbioses play in changes in the endocannabinoidome?

Especially in dysbiosis – that is, an imbalance of the gut flora – changes in the eCBome are observed that are associated with increased intestinal permeability and proinflammatory signaling pathways. The ECS apparently responds adaptively to microbial stimuli by attempting to restore the disturbed homeostasis.

How does the endocannabinoid system affect the composition and function of the gut flora?

Conversely, the endocannabinoid system also influences the conditions under which the gut microbiome exists. Through its effects on motility, secretion, mucosal blood flow, and barrier integrity, the ECS creates a microecological environment that can favor or restrict the colonization and functional activity of certain microorganisms. Additionally, the ECS modulates immunological processes of the intestinal mucosa and thus indirectly affects the microbial composition.

This feedback explains why disturbances in endocannabinoid signaling can accompany not only functional bowel complaints but also changes in the gut flora.

Why is the endocannabinoidome considered an interface between the microbiome and host physiology?

The concept of the endocannabinoidome expands the classical ECS to include numerous bioactive lipids, receptors, and enzymes, some of which are directly or indirectly influenced by microbial metabolites. This creates a complex network in which nutrition, microbiome, immune response, and neuronal regulation are interconnected. The eCBome acts as a molecular interface between microbial signals and host physiology.

How should the clinical evidence regarding the gut microbiome–ECS axis be classified?

The current evidence suggests that the interactions between the gut microbiome and ECS play a central role in the development and maintenance of inflammatory and functional bowel diseases. However, these are mostly mechanistic and preclinical findings. Direct causal relationships in humans are the subject of ongoing research and have so far only been partially demonstrated.

In summary, the gut microbiome–ECS axis forms a dynamic regulatory system that significantly contributes to intestinal balance. This understanding is crucial for further differentiating the potential role of cannabinoids – especially CBD – in the context of gut health and the microbiome.

How do cannabinoids affect basic functions of the digestive tract?

Cannabinoids influence a variety of central functions of the digestive tract. Their effects are predominantly mediated via the endocannabinoid system (ECS) and the extended endocannabinoidome and particularly affect intestinal motility, secretion, barrier function, visceral sensitivity, and inflammatory processes. The existing evidence mainly comes from preclinical studies but is supplemented by individual clinical observations.

In what way do cannabinoids modulate intestinal motility?

A well-established effect of cannabinoids is the regulation of intestinal motility. Endogenous cannabinoids as well as plant-derived cannabinoids predominantly inhibit neuronal excitability in the enteric nervous system. This leads to a reduction in peristalsis and a prolongation of transit time. Physiologically, this mechanism contributes to the fine-tuning of digestion, while under pathological conditions – such as inflammation-induced hyperactivity – it can exert a stabilizing effect.

Influence on secretion and fluid balance

Cannabinoids also modulate the secretion of electrolytes and water into the intestinal lumen. Through neuronal and epithelial signaling pathways, excessive secretory activity can be dampened, which is particularly relevant in connection with diarrheal complaints. Here too, the focus is less on a direct therapeutic effect and more on the homeostatic regulation of disturbed processes.

What influence do cannabinoids have on secretion and fluid balance in the intestine?

Another central aspect is the influence of cannabinoids on the integrity of the intestinal barrier. Through effects on epithelial cells, tight junction structures, and inflammation-relevant signaling pathways, cannabinoids can contribute to the stabilization of the mucosa. These effects are well documented especially in model systems of inflammatory bowel diseases and are discussed as an important mechanism to limit bacterial translocation.

What role do cannabinoids play in immunomodulation and inflammatory processes?

Cannabinoids act on immune cells of the intestinal mucosa, particularly via CB2-mediated signaling pathways. Activation of these receptors is associated with a reduction of proinflammatory cytokine responses and a modulation of local immune activity. This is not a general immunosuppression but a regulatory adjustment of excessive inflammatory reactions.

How do cannabinoids affect visceral sensitivity and pain processing?

The perception of visceral stimuli is also influenced by cannabinoids. Through their action on sensory neurons and neuronal networks of the enteric nervous system, they can modulate sensitivity to stretch and pain stimuli. This effect is particularly relevant in the context of functional bowel disorders, where increased visceral sensitivity plays a central role.

How should cannabinoid effects on the gut be clinically evaluated?

Despite the extensive mechanistic evidence, the transferability to humans must be evaluated with nuance. Clinical studies so far mainly show symptomatic effects, such as on pain, nausea, or bowel habits, while clear disease-modifying effects have not been consistently demonstrated. This underscores the importance of a cautious and evidence-based assessment of cannabinoid effects in the digestive tract. Overall, cannabinoids in the gut do not act in isolation but as part of a complex regulatory system linking neuronal, immunological, and epithelial processes. This multifactorial effect forms the basis for the growing scientific interest in cannabinoids in the context of gut health and functional gastrointestinal disorders.

How are gut flora, inflammation, and the endocannabinoid system connected?

The close functional connection between gut flora, inflammatory processes, and the endocannabinoid system (ECS) represents a central mechanism for maintaining intestinal homeostasis. Current research findings show that the ECS responds to microbial stimuli and is actively involved in regulating inflammatory processes in the gut.

How do microbial signals act as triggers of endocannabinoid signaling pathways?

The gut flora influences the ECS through bacterial metabolites, structural components of the cell wall, as well as indirectly through changes in the intestinal barrier. These signals modulate the synthesis and degradation of endocannabinoids and endocannabinoid-like lipid mediators. With a balanced gut flora, this regulation contributes to the stabilization of the mucosa and a controlled immune response.

In contrast, when dysbiosis occurs, proinflammatory signals are increasingly activated. In this context, studies show altered activity of the ECS, which is interpreted as an adaptive counter-regulation. The system attempts to limit excessive inflammatory reactions and restore barrier function.

To what extent does the endocannabinoid system function as a modulator of intestinal inflammation?

The endocannabinoid system acts predominantly as an inflammation regulator in the gut. Especially CB2 receptors on immune cells of the mucosa play a central role here. Their activation is associated with a reduction of proinflammatory cytokines and modulation of immune cell activity. In parallel, endocannabinoid signaling pathways influence the recruitment of immune cells and the local release of pro-inflammatory mediators.

These effects are well documented in preclinical models of inflammatory bowel diseases and suggest that the ECS is an integral part of the immunological fine regulation in the gut.

What is the significance of the gut barrier as an interface between the microbiome and inflammation?

A key mediating mechanism between gut flora and inflammatory processes is the intestinal barrier. The ECS contributes to stabilizing epithelial integrity by influencing tight junction structures and regulating mucosal permeability. An intact barrier limits the passage of microbial components into the tissue and thus reduces inflammatory reactions.

With impaired barrier function, there is increased translocation of bacterial components, which in turn triggers activation of immunological signaling pathways. In this situation, enhanced endocannabinoid activity is described as part of a compensatory protective mechanism.

How is the interplay between gut flora, inflammation, and the ECS clinically classified?

The existing data suggest that gut flora, inflammation, and the ECS form a closely interconnected regulatory system. While many of these insights come from preclinical studies, clinical observations also show that changes in gut flora and inflammatory processes are often accompanied by altered endocannabinoid signaling.

Overall, the ECS functions as a mediating entity between microbial stimuli and the host's immunological response. This interplay forms the basis for a deeper understanding of chronic inflammatory and functional bowel diseases and is crucial for the later classification of potential cannabinoid-based approaches in the context of gut health.

What role does CBD play in connection with gut health and digestion?

Cannabidiol (CBD) is increasingly discussed in connection with gut health, especially due to its non-psychoactive properties and its diverse molecular mechanisms of action. However, scientific classification requires a clear distinction between preclinical findings, mechanistic assumptions, and clinically verifiable effects in humans.

Through which mechanisms does CBD exert effects in the gastrointestinal system?

CBD does not primarily act through classical CB1 or CB2 receptors but exerts its effects via the extended endocannabinoid system. This includes interactions with TRP channels, PPAR receptors, as well as indirect effects on the breakdown and availability of endogenous cannabinoids. Through these signaling pathways, CBD can influence processes relevant to gut function, such as neuronal excitability, immune activity, and inflammation-associated signal transduction.

What preclinical evidence exists regarding the effect of CBD on gut balance?

In experimental models, CBD shows anti-inflammatory and barrier-stabilizing effects. Animal studies and in vitro investigations suggest that CBD can contribute to reducing proinflammatory reactions and support the integrity of the gut mucosa under inflammatory conditions. Additionally, effects on gut motility and visceral sensitivity are described, especially in stress- or inflammation-associated changes.

These findings provide mechanistic clues but do not yet allow direct conclusions about a regulatory effect of CBD on the gut flora or digestion in humans.

How should the clinical data on CBD and gut flora be evaluated?

The clinical evidence on CBD and gut balance is currently limited. Human studies with isolated, low-dose CBD show no consistent changes in the gut flora, intestinal inflammatory markers, or metabolic parameters. Effects on general digestive function have also not yet been clearly demonstrated. This suggests that possible effects of CBD strongly depend on dose, duration of use, baseline gut condition, and accompanying factors such as diet or stress.

It is also important to distinguish from studies in which cannabis products with multiple cannabinoids were investigated. Results from such studies cannot be directly transferred to pure CBD.

What significance does CBD have for people with sensitive guts?

From today's perspective, CBD cannot be regarded as a general regulator of the gut flora or digestion. Rather, it is discussed as a potentially modulating factor that could influence gut-associated processes under certain conditions – such as inflammatory activation or increased visceral sensitivity. However, this classification remains cautious and evidence-based.

How can CBD be scientifically classified in the context of gut balance?

CBD is not a classic microbiome modulator in the context of gut balance and digestion, but an active ingredient with complex, predominantly indirect effects on the intestinal regulatory system. The current state of research allows a mechanistic classification but no general clinical statements. Further well-designed human studies are needed to reliably define the role of CBD for gut health.

What is meant by a sensitive gut from a functional perspective?

People with sensitive intestines – for example, in the context of functional gastrointestinal complaints or stress-associated digestive disorders – often exhibit increased gut sensitivity, altered gut motility, and heightened perception of visceral signals. In this context, the interplay between the gut microbiome, inflammation regulation, and the endocannabinoid system (ECS) gains particular importance.

What role does the endocannabinoid system play in increased sensitivity of the gut?

A sensitive gut is to be understood less as a structural disease and more as a functional dysregulation. Characteristic are increased neuronal excitability in the enteric nervous system, enhanced low-level immune activation, and a generally impaired barrier function. These factors can reinforce each other and lead to fluctuating symptoms such as bloating, a feeling of pressure, irregular bowel movements, or abdominal pain.

Role of the ECS in increased sensitivity to stimuli

The endocannabinoid system performs a dampening, balancing function in the gut. It modulates neuronal signal transmission, influences visceral sensitivity, and regulates inflammatory processes. In people with sensitive guts, it is assumed that the ECS is increasingly activated to limit excessive stimuli and maintain the balance between the nervous system, immune response, and gut function. Disruptions of this endocannabinoid regulation can contribute to stimuli being perceived more strongly or inflammatory processes lasting longer than physiologically appropriate.

How does the gut flora influence the sensitivity of the intestines?

The gut microbiome also plays a central role in sensitive intestines. Changes in the microbial composition can weaken the barrier function and promote low-grade inflammatory processes. This microbial imbalance in turn affects the ECS, which responds to such changes and tries to intervene compensatorily. This results in a delicate balance that can be easily disturbed in vulnerable individuals.

How is CBD scientifically evaluated for sensitive intestines?

Against this background, CBD is often discussed as a potentially supportive factor. From a scientific perspective, however, it must be noted that CBD cannot be considered a regulatory baseline therapy for gut flora or digestion in people with sensitive guts. Rather, it is classified as a possible modulator of signal processing and inflammation-associated pathways, whose effect strongly depends on individual conditions. Reliable clinical evidence for a general effectiveness is not yet available.

What conclusions can be drawn for people with functional bowel complaints?

For people with sensitive guts, the ECS is a central regulatory system that helps limit excessive signal processing and inflammatory activation. The close interaction with the gut microbiome makes it clear that gut health cannot be viewed in isolation but is the result of a finely tuned interplay of several biological systems. This understanding forms the basis for a nuanced, holistic view of sensitive digestive functions.

Why is the rectum especially prone to inflammatory ailments?

The rectum (rectum and anal canal) represents a functionally highly sensitive section of the digestive tract. In this area, mechanical stress, high microbial density, immunological activity, and pronounced neuronal innervation converge. Accordingly, the rectum is susceptible to inflammatory irritation conditions, which are often accompanied by local complaints such as burning, pressure sensation, pain, or irregular bowel movements.

What role does the microbiome play in the distal intestinal section?

The rectum is inhabited by a particularly dense and functionally active microbial community. These microorganisms are in close contact with the mucosa and influence both the local immune response and the barrier function through their metabolites. A stable microbial balance contributes to mucosal integrity and controlled immune surveillance.

If changes occur in the gut flora, for example due to inflammation, repeated mechanical stimuli, or altered stool passage, the local balance can be disturbed. As a result, immunological signaling pathways are activated that can promote or maintain inflammatory processes in the rectum.

How do inflammatory irritation conditions develop in the rectum?

Inflammatory irritation conditions in the rectum are often characterized by low-grade but persistent inflammatory reactions. These can be accompanied by increased permeability of the mucosa, allowing microbial components to come into easier contact with the immune system. The resulting immune activation, in turn, intensifies local symptoms and can increase the sensitivity of the region.

What functions does the endocannabinoid system perform in the rectum?

The endocannabinoid system (ECS) is also strongly represented in the rectum and performs a regulatory function there. CB1 and CB2 receptors are found in the enteric nervous system, in epithelial structures, and on immune cells of the mucosa. Through these signaling pathways, the ECS influences both neuronal stimulus processing and the local immune response.

In inflammatory processes in the rectum, altered endocannabinoid signaling is observed, which is interpreted as a compensatory response to the inflammation. The goal of this regulation is to limit excessive immune reactions, stabilize the mucosal barrier, and modulate the tissue's sensitivity.

How do the microbiome, inflammation, and ECS influence each other in the rectum?

The interplay between the gut microbiome, inflammation, and ECS is particularly close in the rectum. Microbial signals influence the activity of the ECS, while the ECS in turn shapes the conditions for microbial colonization and the immune response. Disturbances in any of these systems can quickly affect the others and thus exacerbate inflammatory complaints.

How should inflammatory rectal complaints be classified holistically?

Inflammatory complaints in the rectum are rarely monocausal. Rather, they are multifactorial events in which mechanical, microbial, immunological, and neuronal factors interact. The endocannabinoid system acts as a regulatory interface that tries to restore the local balance.

This understanding is central to not viewing inflammatory rectal complaints in isolation but as an expression of disturbed local gut regulation, in which the gut microbiome and endocannabinoid signaling pathways are significantly involved.

Why is a comprehensive view of gut health necessary?

Gut health is increasingly understood as the result of a complex interplay between nutrition, the gut microbiome, and the body's own regulatory systems such as the endocannabinoid system (ECS). A holistic view therefore does not consider individual factors in isolation but their mutual influence—especially with regard to functional complaints and inflammatory processes in the digestive tract.

How does nutrition influence the gut microbiome?

Daily nutrition is one of the strongest influencing factors on the composition and activity of the gut microbiome. A fiber-rich, plant-based diet promotes the formation of short-chain fatty acids and supports stable microbial diversity. These metabolites, in turn, regulate the gut barrier and the local immune response. Conversely, highly processed, high-fat, or unbalanced diets can shift the microbial balance and promote pro-inflammatory signaling pathways.

What role does nutrition play for the endocannabinoid system?

In addition to the microbiome, nutrition also directly influences the ECS. Fatty acid composition, calorie intake, and eating behavior affect the formation of endogenous cannabinoids and related lipid mediators. Certain dietary patterns can increase or normalize endocannabinoid activity and thus modulate indirect processes such as inflammation tendency, barrier function, and visceral sensitivity. Nutrition thus acts as a connecting element between the microbiome and the ECS.

How is CBD to be classified within a holistic gut concept?

Within a holistic perspective, CBD is not classified as a primary regulator of gut flora or digestion, but rather as a potentially complementary factor. Its effects mainly unfold through the extended endocannabinoidome and involve regulatory processes such as inflammation modulation or neuronal signal processing. The existing scientific evidence suggests that CBD does not exert its effects independently of the individual gut environment but is embedded in an existing balance.

Why are individual measures insufficient without considering the overall system?

An isolated consideration of CBD without taking nutrition and the microbiome into account is therefore insufficient. Changes in the gut flora or endocannabinoid signaling cannot be sustainably influenced if fundamental factors such as diet, lifestyle, and stress levels are ignored. Conversely, favorable nutritional and microbiome-related conditions can support the effectiveness of regulatory systems in the gut.

Summary Perspective

The holistic view of nutrition, microbiome, and CBD makes clear that gut health is the result of a dynamic interplay of multiple levels. Nutrition forms the basis for a stable microbiome, which in turn influences immunological and neuronal processes regulated by the ECS. Within this network, CBD can be considered a modulating factor but does not replace fundamental measures to promote gut balance. This integrative understanding is crucial for a realistic and scientifically grounded classification of cannabinoid-related approaches in the context of digestive health.

What integrative perspective emerges for gut health?

Current research increasingly views the endocannabinoid system (ECS) not in isolation but as part of an extended, highly dynamic regulatory network closely linked to the gut microbiome, immunological processes, and metabolic signaling pathways. Especially the concept of the endocannabinoidome (eCBome) shapes new scientific approaches and expands the understanding of potential therapeutic targets in the digestive tract.

What are the current research priorities regarding ECS, gut microbiome, and inflammation?

A central focus is on the bidirectional microbiome–eCBome axis. Studies show that microbial metabolites can influence the concentration and activity of endocannabinoid lipid mediators, while conversely eCBome signaling pathways modulate barrier function, immune response, and neuronal activity of the gut. These relationships are particularly investigated in inflammatory bowel diseases, functional bowel disorders, and stress-associated complaints.

At the same time, barrier integrity is coming into focus as a key mechanism. Research analyzes how endocannabinoid signaling pathways regulate the permeability of the intestinal mucosa and thus can limit inflammatory cascades. In this context, microbial interventions, such as targeted nutritional strategies or probiotics, are also being studied in interaction with the ECS.

What role does the endocannabinoidome play in new research approaches?

CBD is currently being studied primarily as a modulating agent within this complex network. The focus is less on a direct influence on the gut flora and more on indirect effects through anti-inflammatory, neuroprotective, and stress-modulating signaling pathways. Clinical studies in humans have so far shown no consistent effects on the microbiome but provide important insights into safety, dosage, and the distinction between preclinical and clinically relevant evidence.

How is CBD currently being researched in the gastrointestinal context?

In the future, research approaches are expected to be more personalized. Differences in the microbiome, eCBome profile, and inflammatory status could explain why regulatory systems function stably in some people and contribute to functional complaints in others. Furthermore, combined strategies are gaining importance, where nutrition, microbiome modulation, and targeted influence on endocannabinoid signaling pathways are considered together.

Future research will focus less on individual substances or isolated systems and more on the interaction of nutrition, microbiome, and endocannabinoid regulation. In this context, CBD should not be seen as a standalone solution but as a possible component of a complex, individually variable regulatory system. This integrative research approach forms the basis for realistic, evidence-based perspectives in the field of gut health.

Sources:

Hasenoehrl, C., Taschler, U., Storr, M., & Schicho, R. (2016). The gastrointestinal tract - a central organ of cannabinoid signaling in health and disease. Neurogastroenterology and motility, 28(12), 1765–1780. https://doi.org/10.1111/nmo.12931

Lee, Y., Jo, J., Chung, H. Y., Pothoulakis, C., & Im, E. (2016). Endocannabinoids in the gastrointestinal tract. American journal of physiology. Gastrointestinal and liver physiology, 311(4), G655–G666. https://doi.org/10.1152/ajpgi.00294.2015

Duncan, M., Mouihate, A., Mackie, K., Keenan, C. M., Buckley, N. E., Davison, J. S., Patel, K. D., Pittman, Q. J., & Sharkey, K. A. (2008). Cannabinoid CB2 receptors in the enteric nervous system modulate gastrointestinal contractility in lipopolysaccharide-treated rats. American journal of physiology. Gastrointestinal and liver physiology, 295(1), G78–G87. https://doi.org/10.1152/ajpgi.90285.2008

Silvestri, C., & Di Marzo, V. (2023). The Gut Microbiome-Endocannabinoidome Axis: A New Way of Controlling Metabolism, Inflammation, and Behavior. Function (Oxford, England), 4(2), zqad003. https://doi.org/10.1093/function/zqad003

Iannotti, F. A., & Di Marzo, V. (2021). The gut microbiome, endocannabinoids and metabolic disorders. Journal of Endocrinology, 248(2), R83-R97. Retrieved Feb 5, 2026, from https://doi.org/10.1530/JOE-20-0444

Khan, R. N., Maner-Smith, K., A Owens, J., Barbian, M. E., M Jones, R., & R Naudin, C. (2021). At the heart of microbial conversations: endocannabinoids and the microbiome in cardiometabolic risk. Gut microbes, 13(1), 1–21. https://doi.org/10.1080/19490976.2021.1911572

Jansma, J., Brinkman, F., van Hemert, S., & El Aidy, S. (2021). Targeting the endocannabinoid system with microbial interventions to improve gut integrity. Progress in neuro-psychopharmacology & biological psychiatry, 106, 110169. https://doi.org/10.1016/j.pnpbp.2020.110169

Wang, Y., Guo, J., Mao, Z., & Chen, Y. (2025). Symphony of the gut microbiota and endocannabinoidome: a molecular and functional perspective. Frontiers in cellular and infection microbiology, 15, 1566290. https://doi.org/10.3389/fcimb.2025.1566290

Srivastava, R. K., Lutz, B., & Ruiz de Azua, I. (2022). The Microbiome and Gut Endocannabinoid System in the Regulation of Stress Responses and Metabolism. Frontiers in cellular neuroscience, 16, 867267. https://doi.org/10.3389/fncel.2022.867267

Crowley, K., Kiraga, Ł., Miszczuk, E., Skiba, S., Banach, J., Latek, U., Mendel, M., & Chłopecka, M. (2024). Effects of Cannabinoids on Intestinal Motility, Barrier Permeability, and Therapeutic Potential in Gastrointestinal Diseases. International journal of molecular sciences, 25(12), 6682. https://doi.org/10.3390/ijms25126682

Camilleri, M., & Zheng, T. (2023). Cannabinoids and the Gastrointestinal Tract. Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association, 21(13), 3217–3229. https://doi.org/10.1016/j.cgh.2023.07.031

Story, G., Briere, C. E., McClements, D. J., & Sela, D. A. (2023). Cannabidiol and Intestinal Motility: a Systematic Review. Current developments in nutrition, 7(10), 101972. https://doi.org/10.1016/j.cdnut.2023.101972

Srivastava, R. K., Lutz, B., & Ruiz de Azua, I. (2022). The Microbiome and Gut Endocannabinoid System in the Regulation of Stress Responses and Metabolism. Frontiers in cellular neuroscience, 16, 867267. https://doi.org/10.3389/fncel.2022.867267

Hasenoehrl, C., Taschler, U., Storr, M., & Schicho, R. (2016). The gastrointestinal tract - a central organ of cannabinoid signaling in health and disease. Neurogastroenterology and motility, 28(12), 1765–1780. https://doi.org/10.1111/nmo.12931

Ewell, T. R., Bomar, M. C., Abbotts, K. S. S., Kayne, B. T., Risk, B. D., Williams, N. N. B., Wei, Y., Dooley, G. P., Weir, T. L., & Bell, C. (2025). Short-Term Low Dose Cannabidiol Does Not Influence Glucose Tolerance or the Gut Microbiome in Sedentary Adults with Overweight and Obesity: Pilot Study. Cannabis and cannabinoid research, 10.1177/25785125251391085. Advance online publication. https://doi.org/10.1177/25785125251391085

Jansma, J., & El Aidy, S. (2021). Understanding the host-microbe interactions using metabolic modeling. Microbiome, 9(1), 16. https://doi.org/10.1186/s40168-020-00955-1

Thapa, D., Ghimire, A., Warne, L. N., & Carlessi, R. (2025). Targeting the Endocannabinoidome: A Novel Approach to Managing Extraintestinal Complications in Inflammatory Bowel Disease. Pharmaceuticals (Basel, Switzerland), 18(4), 478. https://doi.org/10.3390/ph18040478

Izzo, A. A., & Sharkey, K. A. (2010). Cannabinoids and the gut: new developments and emerging concepts. Pharmacology & therapeutics, 126(1), 21–38. https://doi.org/10.1016/j.pharmthera.2009.12.005

Camilleri, M., & Zheng, T. (2023). Cannabinoids and the Gastrointestinal Tract. Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association, 21(13), 3217–3229. https://doi.org/10.1016/j.cgh.2023.07.031

DiPatrizio N. V. (2021). Endocannabinoids and the Gut-Brain Control of Food Intake and Obesity. Nutrients, 13(4), 1214. https://doi.org/10.3390/nu13041214

Iannotti, F. A., Di Marzo, V., & Petrosino, S. (2016). Endocannabinoids and endocannabinoid-related mediators: Targets, metabolism and role in neurological disorders. Progress in lipid research, 62, 107–128. https://doi.org/10.1016/j.plipres.2016.02.002